Intervention of non-alcoholic fatty liver disease by Ling Gui Zhu Gan Granules and its volatile components through the metabolism of intestinal microbiota and short-chain fatty acids
Journal of Pharmacy and Pharmacology · 2025
DOI: 10.1093/jpp/rgaf070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2025. Verfasst von Nan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Pudong New District, No 1200, Cai lun Road, Shanghai 201203, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Non-alcoholic Fatty Liver Disease, Fatty Acids, Volatile, Drugs, Chinese Herbal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Nation Key Research and Development Program of China, National Natural Science Foundation of China, Shanghai Leading Talents Program.
Abstract (Originalsprache)
Objectives
Ling Gui Zhu Gan (LGZG) Granules is a marketed traditional Chinese medicine compound granule, which is formulated to be consistent with the key quality attributes of the traditional LGZG Decoction. The volatile components are important parts of its preparation process.
Methods
A high-fat diet (HFD)-induced Non-alcoholic fatty liver disease (NAFLD) mouse model was established to evaluate the therapeutic effects of LGZG and preparation of LGZG’s volatile components (IC-LGZG). Gut microbiota composition, Short-chain Fatty Acids (SCFA) levels, and intestinal parameters were assessed, and its correlations were analyzed. Lipopolysaccharide-induced RAW264.7 cells tested anti-inflammatory effects. Key findings LGZG and IC-LGZG significantly reduced HFD-induced body weight gain, improved lipid profiles and liver function, restored gut microbiota balance, increased beneficial bacteria (Akkermansia, Bacteroides, Parabacteroides, Dubosiella, and Bifidobacterium) that produce SCFAs, thereby enhancing SCFA concentrations (acetic acid, propionic acid, and butyric acid), decreased harmful bacteria abundance, and strengthened the intestinal barrier. In vitro studies showed that LGZG, IC-LGZG, and cinnamaldehyde exerted anti-inflammatory effects.
Conclusion
LGZG and its volatile components effectively alleviate the progression of NAFLD by modulating the gut microbiota homeostasis and SCFA levels, and can exert anti-inflammatory effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Pudong New District, No 1200, Cai lun Road, Shanghai 201203, China.
- College of Pharmacy, Anhui University of Traditional Chinese Medicine, Yaohai District, No 350, Long zi hu Road, Hefei 230000, China.
ORCID-Profile: Ling Li
Förderung
- Nation Key Research and Development Program of China
- National Natural Science Foundation of China
- Shanghai Leading Talents Program
- Shanghai Science and Technology Innovation
- Shanghai Rising-Star Program
Zitieren
APA
Wang, N., Li, J., Chen, Z. X., Tang, J., Lim, X. Y., Li, L., & Zhang, T. (2025). Intervention of non-alcoholic fatty liver disease by Ling Gui Zhu Gan Granules and its volatile components through the metabolism of intestinal microbiota and short-chain fatty acids. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf070
Vancouver
Wang N, Li J, Chen ZX, Tang J, Lim XY, Li L, et al. Intervention of non-alcoholic fatty liver disease by Ling Gui Zhu Gan Granules and its volatile components through the metabolism of intestinal microbiota and short-chain fatty acids. Journal of Pharmacy and Pharmacology. 2025. doi:10.1093/jpp/rgaf070
BibTeX
@article{Wang2025,
author = {Wang, Nan and Li, Jing and Chen, Ze-Xuan and Tang, Jie and Lim, Xue-Yee and Li, Ling and Zhang, Tong},
title = {Intervention of non-alcoholic fatty liver disease by Ling Gui Zhu Gan Granules and its volatile components through the metabolism of intestinal microbiota and short-chain fatty acids},
journal = {Journal of Pharmacy and Pharmacology},
year = {2025},
doi = {10.1093/jpp/rgaf070}
}
EUVIMED